A New Blueprint to Halt Bone Growth in a Rare Disease

FOSTER CITY, CA & WILMINGTON, DE – June 04, 2026 – A significant milestone has been reached in the fight against one of the world's most disabling genetic disorders. Mirum Pharmaceuticals and Incyte have announced that pivotal late-stage results for their investigational drug, zilurgisertib, will be unveiled at the prestigious ENDO 2026 conference on June 14. This isn't just another scientific presentation; the data being shared formed the backbone of a New Drug Application that the U.S. Food and Drug Administration has accepted under Priority Review, signaling a potentially transformative advance for patients with Fibrodysplasia Ossificans Progressiva (FOP).

With a regulatory decision deadline set for September 26, 2026, the biotech world and a desperate patient community are watching intently. This development represents a critical juncture for a disease that has long defied medical intervention and for a strategic partnership designed to accelerate innovation in the rare disease space.

The Unyielding Grip of FOP

To understand the significance of zilurgisertib, one must first grasp the devastating reality of Fibrodysplasia Ossificans Progressiva. FOP is an ultra-rare and cruel genetic condition where the body’s repair mechanisms go awry. Instead of healing normally, muscles, tendons, and ligaments progressively turn into solid bone. This process, known as heterotopic ossification (HO), gradually encases individuals in a second skeleton, leading to severe, cumulative disability and a drastically shortened lifespan. Affecting an estimated 900 people worldwide, FOP typically emerges in early childhood, often diagnosed after a tell-tale malformation of the great toes at birth.

Flare-ups of bone growth can be triggered by minor trauma, viral illnesses, or even occur spontaneously, locking joints and robbing patients of their mobility. The unmet medical need is profound. Until August 2023, there were no FDA-approved treatments. The first approval, Sohonos (palovarotene), brought a new option but also came with significant safety warnings, including risks to growing children, highlighting the urgent need for more, and potentially safer, therapeutic avenues.

Targeting the Genetic Blueprint

Zilurgisertib represents a highly targeted approach to disrupting FOP at its source. The disease is driven by a mutation in the ALK2 gene, which produces an overactive ALK2 protein. This protein acts like a switch stuck in the 'on' position, sending continuous signals that drive the runaway bone formation characteristic of FOP. Zilurgisertib is an oral ALK2 inhibitor, a small molecule engineered specifically to block this rogue signal.

By inhibiting the hyperactive ALK2 receptor, the drug is designed to interrupt the chain of events that leads to HO. The upcoming presentation at ENDO 2026 will reveal for the first time the detailed results from Cohort 1 of the pivotal PROGRESS study. This global, placebo-controlled trial evaluated zilurgisertib in patients aged 12 and older. The primary measure of success was straightforward and clinically meaningful: the proportion of patients who developed new bone lesions over a 24-week period, as measured by whole-body CT scans. The acceptance of this data as the basis for an NDA submission suggests the findings are substantial.

“FOP is a devastating, progressive disease that profoundly impacts patients and families,” said Joanne Quan, M.D., Chief Medical Officer at Mirum Pharmaceuticals. “At Mirum, in partnership with Incyte, we are committed to advancing zilurgisertib with urgency as we work toward potentially bringing a needed new treatment option to people living with FOP.”

A Strategic Alliance in the Rare Disease Arena

The story of zilurgisertib is also a case study in modern biotech strategy. The drug was developed by Incyte, a biopharmaceutical powerhouse with deep expertise in drug discovery and development. In April 2026, Incyte granted an exclusive worldwide license for the drug to Mirum Pharmaceuticals. This partnership is a calculated move, leveraging the distinct strengths of each company.

Incyte, having guided the molecule through critical development stages, will continue to lead the ongoing PROGRESS study. Mirum, meanwhile, brings its focused expertise in navigating the complexities of commercializing treatments for rare diseases. With a portfolio that includes the successful launch of LIVMARLI for other rare conditions, Mirum has a proven track record of connecting with patient communities and delivering specialized therapies to market. The deal structure—an upfront payment with future milestones and royalties—allows Incyte to realize value from its R&D investment while empowering a specialist to handle the final leg of the journey.

This collaboration allows Incyte to focus on its broader pipeline in oncology and inflammation while ensuring a promising rare disease asset has a dedicated and experienced champion to carry it across the finish line.

Navigating the Path to Approval

Receiving Priority Review from the FDA is a significant endorsement. This designation is reserved for drugs that, if approved, would represent a major improvement in the safety or effectiveness of treating a serious condition. It shortens the review timeline from the standard ten months to just six, reflecting the agency's recognition of the urgent need in the FOP community. The September 26 PDUFA date now looms as the next critical milestone.

“ENDO 2026 is an important milestone for the zilurgisertib FOP program as we share pivotal results from the PROGRESS study in patients living with this debilitating disease,” stated Steven Stein, M.D., Executive Vice President, Chief Medical Officer and Head of Late-stage Development at Incyte. “These data add to the growing clinical understanding of zilurgisertib’s potential in FOP as Incyte and Mirum continue to advance toward the FDA’s Priority Review PDUFA date.”

Zilurgisertib does not enter the field in a vacuum. The FOP treatment landscape, once barren, is now a dynamic area of research, with several other ALK2 inhibitors and therapies with different mechanisms in clinical trials. The detailed efficacy and safety profile presented at ENDO will be crucial in differentiating zilurgisertib and defining its potential role. For the families and advocates connected through organizations like the International FOP Association (IFOPA), each new development is a source of hope. The upcoming data release and the subsequent FDA decision will determine if that hope is about to translate into a tangible new weapon against this relentless disease.